Literature DB >> 8370695

Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects.

A Giacca1, A Caumo, G Galimberti, G Petrella, M C Librenti, M Scavini, G Pozza, P Micossi.   

Abstract

We and others have shown that in type I diabetes, ip insulin delivery results in lower free insulin levels than sc delivery. The aim of this study was to compare the rate of appearance of insulin in the peripheral circulation during ip and sc insulin administration in type I diabetes, in steady state and nonsteady state. To do this, we determined free insulin levels during ip or sc infusion as well as the impulse response of the insulin system after iv injection of a 6-nmol bolus of insulin. Twelve hours after a constant basal insulin infusion (5.5 +/- 1.4 nmol/h) was started, five C-peptide-negative type I diabetic subjects showed a lower systemic rate of appearance of insulin (expressed as a percentage of the administered dose) with ip than sc administration (27 +/- 6% vs. 40 +/- 10%; P < 0.001). In nonsteady state, when the infusion rate was increased from basal to 15 nmol/h (0-150 min) and subsequently to 42 nmol/h (150-300 min), the percent increase in insulin's systemic rate of appearance was higher with ip than sc infusion (P < 0.05 from 60-150 min; P < 0.01 from 150-300 min), indicating faster absorption. Thus, we conclude that insulin is more rapidly absorbed from the peritoneal cavity than from sc tissue. However, with ip administration, a sizable amount of insulin, once absorbed, is extracted before reaching the peripheral circulation, most likely by the liver. This is indirect evidence that ip insulin delivery results in a portal-peripheral insulin gradient in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370695     DOI: 10.1210/jcem.77.3.8370695

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Clinical hurdles and possible solutions in the implementation of closed-loop control in type 1 diabetes mellitus.

Authors:  Howard Zisser
Journal:  J Diabetes Sci Technol       Date:  2011-09-01

Review 2.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Analysis of "A New Optimized Percutaneous Access System for CIPII".

Authors:  Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2017-04-13

4.  5(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, May 3-5, 2012, Dublin, Ireland.

Authors:  Hilary Hoey; Anita Mlinac; Cam-Tuan Tran; Christof Schlaeger
Journal:  Diabetes Technol Ther       Date:  2012-12       Impact factor: 6.118

Review 5.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

6.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

7.  Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.

Authors:  Susan J Logtenberg; Nanne Kleefstra; Sebastiaan T Houweling; Klaas H Groenier; Reinold O Gans; Evert van Ballegooie; Henk J Bilo
Journal:  Diabetes Care       Date:  2009-05-08       Impact factor: 17.152

8.  Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons.

Authors:  Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2008-07

Review 9.  Implantable insulin pumps and metabolic control.

Authors:  K D Hepp
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

Review 10.  Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.

Authors:  A L McCall; L S Farhy
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.